Phase 3
Completed N=336
Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
Source: ClinicalTrials.gov NCT00142584 ↗Enrolled (actual)
336
Serious AEs
3.9%
Results posted
Mar 2022
Primary outcomePrimary: Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline — -14.0; -10.9 mm Hg
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline |
-14.0; -10.9 | — |
| SECONDARY Change From Baseline in Mean Trough Sitting Diastolic Blood Pressure (DBP) at Each Study Visit (Visits 1 Through 9) Compared to Baseline |
-8.3; -8.4; -8.4; -8.4; -10.6; -9.8 | — |
| SECONDARY Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
150; 51 | — |
Eligibility Criteria
Inclusion Criteria
- Completion of previous nebivolol study
- Stage 1-2 Hypertension (HTN) at baseline of first study
Exclusion Criteria
- Recent myocardial infarction or stroke
- Contraindications to beta blocker therapy
Data sourced from ClinicalTrials.gov (NCT00142584). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.